Diapride M1 Tablets (Glimepiride + Metformin )

• Composition :
  Each tablet contains Glimepiride 1 mg + Metformin 500 mg SR Tablets (in Sustained Release form).
• Indications :
  For patients with type II diabetes mellitus when diet exercise & single agent does not result in adequate glycemic control.
• Pharmacodynamics :
  The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. In addition, extra-pancreatic effects may also play a role in the activity of sulphonylureas such as glimepiride.Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Hence, the combination of glimepiride and metformin sustained-release complements each other and provides better glycemic control in management of type-2 diabetes.
• Dosage and administration :
  One tablet once daily with breakfast or first main meal of the day
• Contraindications :
  Contraindicated in patients with known hypersensitivity to the drug.Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.
• Precautions and warnings :
  Glimepiride is a sulfonylurea agent, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients should be warned against excessive alcohol intake, while receiving metformin. Regular monitoring of thyroid-stimulating hormone (TSH) levels is recommended inpatients with hypothyroidism. Long-term treatment with metformin has been associated with a decrease invitamin B12 serum levels
• Use in pregnancy, lactation & pediatrics :
  There are no adequate and well-controlled studies in human pregnancy, lactation & children.
• Drug interactions :
  Miconazole and phenylbutazoneincreases hypoglycemic effect of glimepiride.If salicylates are administered or discontinued in patients receiving oral antidiabetic agents, patients should be monitored for hypoglycemia or loss of blood glucose control.
• Adverse reactions :
  The adverse effects includehypoglycaemia, nausea, diarrhoea, abdominal pain, constipation, vomiting and metallic taste in mouth.
• Therapy Area :
  Anti-Diabetic agents